NO20054526L - Forebygging og behandling av brystkreft med 4-hydroxy tamoxifen - Google Patents

Forebygging og behandling av brystkreft med 4-hydroxy tamoxifen

Info

Publication number
NO20054526L
NO20054526L NO20054526A NO20054526A NO20054526L NO 20054526 L NO20054526 L NO 20054526L NO 20054526 A NO20054526 A NO 20054526A NO 20054526 A NO20054526 A NO 20054526A NO 20054526 L NO20054526 L NO 20054526L
Authority
NO
Norway
Prior art keywords
breast cancer
treatment
cancer prevention
hydroxy tamoxifen
hydroxytamoxifen
Prior art date
Application number
NO20054526A
Other languages
English (en)
Other versions
NO333805B1 (no
Inventor
Jacques Wepierre
Philippe Rouanet
Dominique Salin-Drouin
Original Assignee
Besins Int Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Besins Int Lab filed Critical Besins Int Lab
Publication of NO20054526L publication Critical patent/NO20054526L/no
Publication of NO333805B1 publication Critical patent/NO333805B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Foreliggende oppfinnelse fremskaffer fremgangsmåter for behandling og forhindring av brystkreft ved adminisfrering av 4-hydroksytamoxifen til en pasient. Den fremskaffer også farmasøytiske sammensetninger av 4-hydroksytamoxifen som passer for perkutan adminisfrasjon. Når perkutant adminisfrert til en pasients bryst, konsentteres hydroksytamoxifen lokalt og utøver en anti-østtogenisk effekt. I pasienter med brystcancer reduserer denne effekten tumorproliferasjonen. I pasienter med risiko for utvikling av brystcancer, forhindrer den anti-østtogene effekten dannelse av tumorer.
NO20054526A 2003-04-01 2005-09-30 Anvendelse av 4-hydroxy tamoxifen for fremstilling av et medikament, og farmasoytiske sammensetninger NO333805B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45896303P 2003-04-01 2003-04-01
PCT/EP2003/015029 WO2004087123A1 (en) 2003-04-01 2003-12-15 Prevention and treatment of breast cancer with 4-hydroxy tamoxifen

Publications (2)

Publication Number Publication Date
NO20054526L true NO20054526L (no) 2005-09-30
NO333805B1 NO333805B1 (no) 2013-09-16

Family

ID=33131847

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054526A NO333805B1 (no) 2003-04-01 2005-09-30 Anvendelse av 4-hydroxy tamoxifen for fremstilling av et medikament, og farmasoytiske sammensetninger

Country Status (11)

Country Link
US (2) US7704516B2 (no)
EP (3) EP1608353B1 (no)
JP (1) JP5490346B2 (no)
AU (1) AU2003294973B2 (no)
CA (1) CA2519980C (no)
ES (3) ES2483896T3 (no)
IL (1) IL170807A (no)
MX (1) MXPA05010597A (no)
NO (1) NO333805B1 (no)
NZ (1) NZ542499A (no)
WO (1) WO2004087123A1 (no)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO337298B1 (no) * 2004-03-22 2016-03-07 Besins Healthcare Lu Sarl Kjemisk stabile preparater av 4-hydroksytamoksifen

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1572178B1 (en) * 2002-12-18 2006-05-03 Laboratoires Besins International Treatment of mastalgia with 4-hydroxy tamoxifen
EP1952809B1 (en) * 2002-12-18 2017-08-02 Besins Healthcare Luxembourg SARL Formulations for the reduction of breast density with 4-Hydroxy Tamoxifen
ES2483896T3 (es) * 2003-04-01 2014-08-08 Besins Healthcare Luxembourg Sarl Prevención y tratamiento de cáncer de seno con 4-hidroxi tamoxifen
NZ544031A (en) * 2003-06-09 2008-08-29 Univ Northwestern Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
EP1579856A1 (en) * 2004-03-22 2005-09-28 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1748770B1 (en) * 2004-03-22 2008-04-09 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
US7507769B2 (en) 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
DK1799201T3 (da) * 2004-10-14 2009-03-30 Besins Int Lab 4-Hydroxy-tamoxifen gelformuleringer
EP1647271A1 (en) * 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations
EP2147674A1 (en) * 2008-07-24 2010-01-27 Besins Healthcare Transdermal pharmaceutical compositions comprising danazol
US10080760B2 (en) 2009-10-27 2018-09-25 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising active agents
EP3143392B1 (en) 2014-05-12 2023-02-22 Quest Diagnostics Investments Incorporated Quantitation of tamoxifen metabolites by mass spectrometry
KR101571098B1 (ko) 2014-07-16 2015-11-23 건국대학교 산학협력단 타목시펜 및 메틸설포닐메탄을 유효성분으로 포함하는 암 질환 예방 또는 치료용 약학 조성물
WO2016094854A2 (en) * 2014-12-12 2016-06-16 Miradx Methods for treating or preventing cancer in a kras-variant patient and for diagnosing risk of developing multiple primary breast tumors
CA3022377A1 (en) 2016-04-29 2017-11-02 Board Of Regents, The University Of Texas System Targeted measure of transcriptional activity related to hormone receptors
SG11202002105WA (en) 2017-09-11 2020-04-29 Atossa Therapeutics Inc Methods for making and using endoxifen
WO2020023616A1 (en) * 2018-07-24 2020-01-30 Cornell University Methods of upregulating tiparp as anticancer strategies
JP7662204B2 (ja) 2019-07-03 2025-04-15 アトッサ・セラピューティクス・インコーポレイテッド エンドキシフェンの徐放性組成物
WO2025019830A1 (en) * 2023-07-19 2025-01-23 Atossa Therapeutics, Inc. Anti-tumor compounds and methods of use thereof and synthesis thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2558373B1 (fr) * 1984-01-20 1987-07-03 Mauvais Jarvis Pierre Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
ES2044860T3 (es) 1987-04-21 1994-01-16 Heumann Pharma Gmbh & Co Estables aductos con disolventes de z-1-(p-beta-di-metil-amino-etoxi-fenil)-1-(p-hidroxi-fenil)-2-fenil-but-1-eno.
US5045553A (en) 1987-06-24 1991-09-03 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter
DE3836862A1 (de) 1988-10-27 1990-05-03 Schering Ag Mittel zur transdermalen applikation von steroidhormonen
US5189212A (en) 1990-09-07 1993-02-23 University Of Georgia Research Foundation, Inc. Triarylethylene carboxylic acids with estrogenic activity
TW218849B (no) * 1991-05-17 1994-01-11 Bristol Myers Squibb Co
US5613958A (en) 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
DE4407742C1 (de) 1994-03-08 1995-06-22 Hexal Pharma Gmbh Transdermales System in Form eines Pflasters mit einem Tamoxifen-Derivat
US5720963A (en) * 1994-08-26 1998-02-24 Mary Kay Inc. Barrier disruption treatments for structurally deteriorated skin
WO1997036570A1 (de) 1996-03-29 1997-10-09 S.W. Patentverwertungs Ges. M.B.H. Edelsbacher U. Partner Kosmetikum bzw. kosmetikzusammensetzung zur glättung und straffung der haut bei gestörtem unterhaut-binde-fettgewebe, insbesondere bei der 'cellulite'
AU2513899A (en) 1997-12-23 1999-07-19 Hexal Ag Mixture and pharmaceutical composition comprising z-4-hydroxytamoxifen and cyclodextrin
US6013270A (en) * 1998-04-20 2000-01-11 The Procter & Gamble Company Skin care kit
CN100482216C (zh) 1999-12-16 2009-04-29 德马全兹股份有限公司 氢氧根释放剂增强透皮渗透的用途
DE10033853A1 (de) 2000-07-12 2002-01-31 Hexal Ag Transdermales therapeutisches System mit hochdispersem Siliziumdioxid
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
AU2002340120A1 (en) 2001-10-04 2003-04-14 Cellegy Pharmaceuticals, Inc. Semisolid topical hormonal compositions and methods for treatment
DK1317921T3 (da) 2001-12-07 2009-12-21 Besins Mfg Belgium Farmaceutisk sammensætning i form af en gel eller oplösning med dihydrotestosteron, fremgangsmåde til fremstilling og anvendelser heraf
EP1952809B1 (en) * 2002-12-18 2017-08-02 Besins Healthcare Luxembourg SARL Formulations for the reduction of breast density with 4-Hydroxy Tamoxifen
EP1572178B1 (en) 2002-12-18 2006-05-03 Laboratoires Besins International Treatment of mastalgia with 4-hydroxy tamoxifen
ES2483896T3 (es) 2003-04-01 2014-08-08 Besins Healthcare Luxembourg Sarl Prevención y tratamiento de cáncer de seno con 4-hidroxi tamoxifen
NZ544031A (en) 2003-06-09 2008-08-29 Univ Northwestern Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen
US7968532B2 (en) 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
US20050208139A1 (en) 2004-03-22 2005-09-22 Ascend Therapeutics, Inc. Chemically stable compositions of 4-hydroxy tamoxifen
US7507769B2 (en) 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1579856A1 (en) 2004-03-22 2005-09-28 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1647271A1 (en) 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO337298B1 (no) * 2004-03-22 2016-03-07 Besins Healthcare Lu Sarl Kjemisk stabile preparater av 4-hydroksytamoksifen

Also Published As

Publication number Publication date
HK1086193A1 (en) 2006-09-15
HK1119950A1 (en) 2009-03-20
US20090186944A1 (en) 2009-07-23
WO2004087123A1 (en) 2004-10-14
CA2519980C (en) 2012-04-10
US7704516B2 (en) 2010-04-27
US8475814B2 (en) 2013-07-02
EP1608353B1 (en) 2014-04-30
NO333805B1 (no) 2013-09-16
ES2483896T3 (es) 2014-08-08
EP1952810B1 (en) 2014-01-08
AU2003294973A1 (en) 2004-10-25
JP5490346B2 (ja) 2014-05-14
CA2519980A1 (en) 2004-10-14
EP1941871A1 (en) 2008-07-09
EP1941871B1 (en) 2014-01-08
AU2003294973B2 (en) 2010-05-13
MXPA05010597A (es) 2006-03-09
US20050031695A1 (en) 2005-02-10
JP2006514967A (ja) 2006-05-18
ES2456957T3 (es) 2014-04-24
ES2456958T3 (es) 2014-04-24
EP1952810A1 (en) 2008-08-06
IL170807A (en) 2014-08-31
EP1608353A1 (en) 2005-12-28
NZ542499A (en) 2008-10-31

Similar Documents

Publication Publication Date Title
MXPA05010597A (es) Prevencion y tratamiento de cancer de mama con tamoxifen 4-hidroxi.
BR0209147A (pt) Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais
ZA200802811B (en) Therapy for the treatment of disease
BR0316685A (pt) Composições e métodos para a administração aperfeiçoada por via mucosal de peptìdeos fixadores ao receptor de y2 e métodos para tratar e prevenir a obesidade
ZA200409388B (en) Methods and compositions using immunodulatory compounds for treatment and management of cancers and other diseases
MXPA05012155A (es) Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de canceres y otras enfermedades.
TW200500355A (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
BRPI0512213A (pt) método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
DK1169059T3 (da) Docetaxel i kombination med rhuMAb HER2 til behandling af cancere
BRPI0512220A (pt) método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
BRPI0414736A (pt) 5-aril-pirimidinas como agentes anticáncer
RU2007138867A (ru) Режимы дозирования транс-кломифена
RU2011151854A (ru) Новые терапевтические способы применения инекальцитола
EA201270298A1 (ru) Способ лечения злокачественной опухоли
PT1638492E (pt) Tratamento pré-operatório da dor pós-operatória
WO2002074756A3 (de) Urokinase-inhibitoren
NO20062904L (no) Anvendelse av 4-hydroksy tamoxifen for fremstilling av et medikament for behandling av gynekomasti
MX2010006310A (es) O-desmetil-venlafaxina para el tratamiento de transtorno depresivo mayor.
NO20064609L (no) Behandling og forhindring av godartet brystsykdom med 4-hydroksytamoksifen
BR112022001814A2 (pt) Métodos de tratamento de câncer multifocal
RU2519120C1 (ru) Способ профилактики скелетных осложнений у больных с литическими метастазами в плоские и смешанные кости
ATE354373T1 (de) Verabreichung von gammaglobulinen zur behandlung von lymphomen
RU2003107771A (ru) Способ комбинированного лечения рака легкого iii стадии
Vidal et al. Triton tumor in a patient with neurofibromatosis-1: a clinical case
Sahhu PD. 248 Nonmelanoma skin cancers

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: BESINS HEALTHCARE LUXEMBOURG, LU

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: BENSINS HEALTHCARE LUXEMBOURG SARL, LU

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: BESINS HEALTHCARE LUXEMBOURG SARL, LU

MK1K Patent expired